# 21 CFR 330.14 Additional criteria and procedures for classifying OTC drugs as generally recognized as safe and effective and not misbranded.

21 CFR 330.14 Additional criteria and procedures for classifying OTC drugs as generally recognized as safe and effective and not misbranded., “Additional criteria and procedures for classifying OTC drugs as generally recognized as safe and effective and not…”, is a CFR section of [21 CFR Part 330, Subpart B—Administrative Procedures](https://ontology.bommaritollc.com/id/01a0f094-b5ff-7515-b033-d203cc5fd360); in force.

IRI: <https://ontology.bommaritollc.com/id/01a0f094-c51f-71ff-a01e-42493ca9cf85>

Within: [Title 21—Food and Drugs](https://ontology.bommaritollc.com/id/01a0f094-b437-7426-9a1d-f0a9f3d3e1aa) › [21 CFR Chapter I—FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES](https://ontology.bommaritollc.com/id/01a0f094-b455-74b7-9458-ed95d7b5ea58) › [21 CFR Chapter I, Subchapter D—DRUGS FOR HUMAN USE](https://ontology.bommaritollc.com/id/01a0f094-b5e4-722f-99b0-5c1856aef2a9) › [21 CFR Part 330—Over-the-counter (OTC) human drugs which are generally recognized as safe and effective and not misbranded](https://ontology.bommaritollc.com/id/01a0f094-b854-766e-89d3-a11bb4699b7e) › [21 CFR Part 330, Subpart B—Administrative Procedures](https://ontology.bommaritollc.com/id/01a0f094-b5ff-7515-b033-d203cc5fd360)

Type: [schema:Legislation](https://schema.org/Legislation)

- `adms:identifier`: [cfr-section 21 CFR 330.14](https://ontology.bommaritollc.com/id/01a0f094-c520-772f-a311-db3f56e31dc0)
- `eli:cites`:
  - [5 U.S.C. 552 Public information; agency rules, opinions, orders, records, and proceedings](https://ontology.bommaritollc.com/id/01a0edf4-5b27-7466-a019-fef93b12cea0)
  - [18 U.S.C. 1905 Disclosure of confidential information generally](https://ontology.bommaritollc.com/id/01a0f06a-9b21-77e5-b0e9-4b07425345ef)
  - [21 U.S.C. 331 Prohibited acts](https://ontology.bommaritollc.com/id/01a0f06c-cc92-7163-972f-ca345be44724)
  - [21 CFR Part 50—Protection of human subjects](https://ontology.bommaritollc.com/id/01a0f094-b7f0-7092-8cfc-6d60da0417f5)
  - [21 CFR Part 54—Financial disclosure by clinical investigators](https://ontology.bommaritollc.com/id/01a0f094-b7f1-7756-81e5-d0b27d4498d1)
  - [21 CFR Part 56—Institutional Review Boards](https://ontology.bommaritollc.com/id/01a0f094-b7f2-72a4-82d6-ac180848fce4)
  - [21 CFR Part 58—Good laboratory practice for nonclinical laboratory studies](https://ontology.bommaritollc.com/id/01a0f094-b7f3-722a-bdd9-43216f95ec63)
  - [21 CFR 10.20 Submission of documents to Dockets Management Staff; computation of time; availability for public disclosure.](https://ontology.bommaritollc.com/id/01a0f094-ba67-70e4-a06b-b709873162f9)
  - [21 CFR 25.30 General.](https://ontology.bommaritollc.com/id/01a0f094-bb91-7368-898e-36fe349f7c44)
  - [21 CFR 25.31 Human drugs and biologics.](https://ontology.bommaritollc.com/id/01a0f094-bb92-7065-981f-4d5ba7337f0c)
  - [21 CFR 25.40 Environmental assessments.](https://ontology.bommaritollc.com/id/01a0f094-bb96-753f-a17a-23785c940d8f)
  - [21 CFR 310.305 Records and reports concerning adverse drug experiences on marketed prescription drugs for human use without approved new drug applications.](https://ontology.bommaritollc.com/id/01a0f094-c474-7610-a946-2e3b0d6f0dc9)
  - [21 CFR 310.502 Certain drugs accorded new drug status through rulemaking procedures.](https://ontology.bommaritollc.com/id/01a0f094-c477-76a3-8566-b306b8d773b9)
  - [21 CFR 314.80 Postmarketing reporting of adverse drug experiences.](https://ontology.bommaritollc.com/id/01a0f094-c4c4-715e-9bae-f809f18f5dcb)
  - [21 CFR 330.10 Procedures for classifying OTC drugs as generally recognized as safe and effective and not misbranded, and for establishing monographs.](https://ontology.bommaritollc.com/id/01a0f094-c51c-7732-a34d-0ca422e48582)
  - [21 CFR 330.15 Timelines for FDA review and action on time and extent applications and safety and effectiveness data submissions.](https://ontology.bommaritollc.com/id/01a0f094-c520-772f-a311-db4169158678)
- `prov:wasDerivedFrom`:
  - [evidence from https://www.govinfo.gov/app/details/CFR-2025-title21-vol1](https://ontology.bommaritollc.com/id/01a0f094-c51f-71ff-a01e-42489495a688)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f094-e334-72ff-9528-171f1e778670)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f0d0-c55d-7422-ac3c-7e5276f405e8)
  - [evidence from https://www.govinfo.gov/link/cfr/21/330?sectionnum=14&year=mostrecent&link-type=details](https://ontology.bommaritollc.com/id/01a10f17-67e8-7697-a797-26bc8b002a98)
- `schema:isPartOf`: [21 CFR Part 330, Subpart B—Administrative Procedures](https://ontology.bommaritollc.com/id/01a0f094-b5ff-7515-b033-d203cc5fd360)
- `schema:legislationIdentifier`: 21 CFR 330.14
- `schema:legislationJurisdiction`: [United States](https://ontology.bommaritollc.com/id/01a0ed8e-f797-7004-b7f5-bec2695977c0)
- `schema:legislationLegalForce`: [schema:InForce](https://schema.org/InForce)
- `schema:legislationType`: [CFR section](https://ontology.bommaritollc.com/vocab/leg/cfrSection)
- `schema:name`: Additional criteria and procedures for classifying OTC drugs as generally recognized as safe and effective and not misbranded
- `schema:url`: [https://www.govinfo.gov/link/cfr/21/330?sectionnum=14&year=mostrecent&link-type=details](https://www.govinfo.gov/link/cfr/21/330?sectionnum=14&year=mostrecent&link-type=details)
- `skos:prefLabel`: 21 CFR 330.14 Additional criteria and procedures for classifying OTC drugs as generally recognized as safe and effective and not misbranded.

## Elsewhere

- [Official page](https://www.govinfo.gov/link/cfr/21/330?sectionnum=14&year=mostrecent&link-type=details) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/CFR-2025-title21-vol1) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/) (www.govinfo.gov)

## Pointing here

- Cited by (7; `eli:cites`):
  - [21 CFR 330.13 Conditions for marketing ingredients recommended for over-the-counter (OTC) use under the OTC drug review.](https://ontology.bommaritollc.com/id/01a0f094-c51e-7389-b94a-5428ce980a4d)
  - [21 CFR 330.15 Timelines for FDA review and action on time and extent applications and safety and effectiveness data submissions.](https://ontology.bommaritollc.com/id/01a0f094-c520-772f-a311-db4169158678)
  - [21 U.S.C. 355h Regulation of certain nonprescription drugs that are marketed without an approved drug application](https://ontology.bommaritollc.com/id/01a0f06c-cce3-7057-a5e9-bb0e6598808a)
  - [21 U.S.C. 360fff Definitions](https://ontology.bommaritollc.com/id/01a0f06c-cd61-7183-807e-9bc08077975d)
  - [21 U.S.C. 360fff-2 Eligibility determinations; data submission; filing](https://ontology.bommaritollc.com/id/01a0f06c-cd64-7691-b9f0-7cc3d64ff081)
  - [21 U.S.C. 360fff-3 GRASE determination](https://ontology.bommaritollc.com/id/01a0f06c-cd64-7691-b9f0-7cd33d11828c)
  - [21 U.S.C. 360fff-6 Non-sunscreen time and extent applications](https://ontology.bommaritollc.com/id/01a0f06c-cd68-739c-9696-ffa9475e4861)

---
Also as: [Turtle](https://ontology.bommaritollc.com/id/01a0f094-c51f-71ff-a01e-42493ca9cf85.ttl), [JSON-LD](https://ontology.bommaritollc.com/id/01a0f094-c51f-71ff-a01e-42493ca9cf85.jsonld), [N-Triples](https://ontology.bommaritollc.com/id/01a0f094-c51f-71ff-a01e-42493ca9cf85.nt), [HTML](https://ontology.bommaritollc.com/id/01a0f094-c51f-71ff-a01e-42493ca9cf85)
Cite as: 21 CFR 330.14 Additional criteria and procedures for classifying OTC drugs as generally recognized as safe and effective and not misbranded.. bc-ontology, release 0.1.0-rc38, 2026-10-21. https://ontology.bommaritollc.com/id/01a0f094-c51f-71ff-a01e-42493ca9cf85
Release 0.1.0-rc38, graph hash 05350a11cf9d0c42fba51e92b877115781ab65cb92afcd6b172ff9f8f4abf0bd.
